Theravance Biopharma
TBPH
TBPH
94 hedge funds and large institutions have $1.84B invested in Theravance Biopharma in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.41% more ownership
Funds ownership: 85.37% → 86.78% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
47% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.99M
Holders
94
Holding in Top 10
5
Calls
$1.06M
Puts
$1.99M
Top Buyers
| 1 | +$38.5M | |
| 2 | +$36.8M | |
| 3 | +$6.26M | |
| 4 |
BlackRock
New York
|
+$4.86M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.5M |
Top Sellers
| 1 | -$18.3M | |
| 2 | -$14.2M | |
| 3 | -$6.97M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.34M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.13M |